A Phase Ib clinical trial for treatment of Idiopathic Pulmonary Fibrosis (IPF)
Latest Information Update: 17 Mar 2025
At a glance
- Drugs RC 0315 (Primary)
- Indications Idiopathic pulmonary fibrosis
- Focus Adverse reactions; First in man; Therapeutic Use
Most Recent Events
- 12 Mar 2025 According to Remedy Cell media release, Remedy Cell and Qureight collaborated to validate RC-0315's mechanism of action in idiopathic pulmonary fibrosis (IPF).
- 19 Mar 2024 New trial record
- 15 Mar 2024 According to a Pluri Inc media release, PluriCDMO has signed a manufacturing agreement with Remedy Cell Ltd and will support Remedy Cell's production team to initiate a phase Ib clinical trial RC-0315 for the treatment of Idiopathic Pulmonary Fibrosis (IPF) in early 2025.